

# Natural Killer Cells -Competitive Landscape, Technology and Pipeline Analysis, 2017

<https://marketpublishers.com/r/NE98726164EEN.html>

Date: November 2017

Pages: 207

Price: US\$ 2,750.00 (Single User License)

ID: NE98726164EEN

## Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Natural Killer Cells- Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Natural Killer Cells.

This report provides information on the therapeutic development based on Natural Killer Cells mechanism of action dealing with around 40+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight's Report also assesses the Natural Killer Cells therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 22+ active companies involved in the therapeutic development of the products.

## SCOPE

The report provides competitive pipeline landscape of Natural Killer Cells

The report provides the marketed drugs information including its sales, development activities and details of patent expiry

The report provides the insight of current and future market for Natural Killer Cells

The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

Coverage of the Natural Killer Cells pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

The report reviews key players involved in the therapeutics development for Natural Killer Cells and also provide company profiling

The report also gives the information of dormant pipeline projects

Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

## **REASONS TO BUY**

Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

Complete MOA intelligence and complete understanding over therapeutics development for Natural Killer Cells

Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.

Devise corrective measures for pipeline projects by understanding Natural Killer Cells pipeline depth and focus of Indication therapeutics

Developing strategic initiatives to support your drug development activities.

Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

## Contents

- Executive Summary Snapshot Report
- Executive Summary
- Natural Killer Cells Overview
- Analysis of NK cells based therapies
- NK Cells Receptors and Shares
- Percentage Share of NK Cell Based Therapeutics
- Targets of Natural Killer Cells Based Therapies and Their Analysis
- NK Cells Based Therapy Collaborations
- Collaborations and Deal Year
- Collaborations and Deal value
- Licensing Agreement for future development of NK Cell Therapy
- Financing details of NK cells based therapies
- Companies received Grants for NK cells based therapies
- Designation
- Institutes involved in NK cells based therapies
- Technologies Involved in NK Cells Based Therapies
- Clinical trials & Completion Year
- Phase III Drugs
- Phase II Drugs
- Phase I Drugs
- Recent Trends in NK Cells Therapy
- Leading Companies and their Shares in Natural Killer cells Therapeutics
- Market Drivers
- Market Barriers
- SWOT Analysis
- Pipeline Therapeutics
- Therapeutics under Development by Companies
- Late Stage Products (Phase III)
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Pre-Clinical and Discovery Products
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Monotherapy Products

Assessment by Combination Products  
Assessment by Route of Administration  
Assessment by Stage and Route of Administration  
Assessment by Molecule Type  
Assessment by Stage and Molecule Type  
Assessment by Domain  
Assessment by Stage and Domain  
Appendix  
Report Methodology  
DelveInsight Consulting Services  
About DelveInsight  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

- Table 1: Receptors of NK cells
- Table 2: Type of NK Cells Receptors
- Table 3: Targets and Number of Products
- Table 4: Natural Killer Cells based therapies -Target Antigens and Companies
- Table 5: Collaboration and Deal Values for NK cell therapy, 2017
- Table 6: Licensing Agreement for future development of NK Cell Therapy, 2017
- Table 7: Companies of NK cells based therapies financing for future developments, 2017
- Table 8: Companies of NK cells received grants, 2017
- Table 9: Analysis of Natural killer cells on the basis of Designation, 2017
- Table 10: Institute involved in NK Cells, 2017
- Table 11: Companies and their technologies for NK cell therapy, 2017
- Table 12: Natural Killer Cell based therapies -Trial Completion Year, Phase, Drug and Company, 2017
- Table 13: SWOT analysis of NK Cells Based Therapies, 2017
- Table 14: Number of Products Under Development for Natural Killer Cells Therapies, 2017
- Table 15: Number of Products under development by Companies, 2017
- Table 16: Late Stage Products (Phase III and Filed), 2017
- Table 17: Mid Stage Products (Phase II), 2017
- Table 18: Early Stage Products (Phase I), 2017
- Table 19: Pre-Clinical and Discovery Products, 2017
- Table 20: Assessment by Monotherapy Products, 2017
- Table 21: Assessment by Combination Products, 2017
- Table 22: Assessment by Route Of Administration, 2017
- Table 23: Assessment by Stage and Route Of Administration, 2017
- Table 24: Assessment by Molecule Type, 2017
- Table 25: Assessment by Stage and Molecule Type, 2017
- Table 26: Assessment by Stage of development and Domain, 2017
- Table 27: Assessment by Stage of development and Domain, 2017

## List Of Figures

### LIST OF FIGURES

Figure 1: Mechanism of action

Figure 2: Types of NK Cell Receptors and Share of products, 2017

Figure 3: Percentage Share of NK Cell Therapeutics, 2017

Figure 4: Target of NK cells and number of products, 2017

Figure 5: Natural Killer Cell based therapies -Number of Products (N) and Stages of Development, 2017

Figure 6: NK Cells Therapy Collaborations and Deal Year, 2017

Figure 7: Collaboration and deal value, 2017

Figure 8: Financing and deal value, 2017

Figure 9: NK Cells based therapies designation and Number of Products, 2017

Figure 10: Technologies Involved in NK Cells Based Therapies with their companies, 2017

Figure 11: Natural Killer Cell based therapies -Study Completion Date, Indication and Recruitment status of Phase III Drugs, 2017

Figure 12: Natural Killer Cell based therapies -Study Completion Date, Indication and Recruitment status of Phase II Drugs, 2017

Figure 13: Natural Killer Cell based therapies - Study Completion Date, Indication and Recruitment status of Phase-I Drugs, 2017

Figure 14: Natural Killer Cell based therapies -Number of Trials (N) and Study Completion Year, 2017

Figure 15: Leading NK Cells based therapies companies and Shares, 2017

Figure 16: Number of Products under Development for Natural Killer Cells Therapies, 2017

Figure 17: Late Stage Products (Phase III), 2017

Figure 18: Mid Stage Products (Phase II), 2017

Figure 19: Early Stage Products (Phase I), 2017

Figure 20: Pre-Clinical and Discovery Products, 2017

Figure 21: Assessment by Monotherapy Products, 2017

Figure 22: Assessment by Combination Products, 2017

Figure 23: Assessment by Route of Administration, 2017

Figure 24: Assessment by Stage and Route of Administration, 2017

Figure 25: Assessment by Molecule Type, 2017

Figure 26: Assessment by Stage and Molecule Type, 2017

Figure 27: Assessment by Domain, 2017

Figure 28: Assessment by Stage and Domain, 2017

## I would like to order

Product name: Natural Killer Cells -Competitive Landscape, Technology and Pipeline Analysis, 2017

Product link: <https://marketpublishers.com/r/NE98726164EEN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/NE98726164EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970